Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Junctional adhesion molecule C (JAM-C) (JAM-2) (Junctional adhesion molecule 3) (JAM-3)

 JAM3_HUMAN              Reviewed;         310 AA.
Q9BX67; B3KWG9; Q8WWL8; Q96FL1;
31-AUG-2004, integrated into UniProtKB/Swiss-Prot.
01-JUN-2001, sequence version 1.
25-OCT-2017, entry version 150.
RecName: Full=Junctional adhesion molecule C;
Short=JAM-C;
AltName: Full=JAM-2;
AltName: Full=Junctional adhesion molecule 3;
Short=JAM-3;
Flags: Precursor;
Name=JAM3; ORFNames=UNQ859/PRO1868;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH JAM2, AND
TISSUE SPECIFICITY.
TISSUE=Brain;
PubMed=11590146; DOI=10.1074/jbc.M105972200;
Arrate M.P., Rodriguez J.M., Tran T.M., Brock T.A., Cunningham S.A.;
"Cloning of human junctional adhesion molecule 3 (JAM3) and its
identification as the JAM2 counter-receptor.";
J. Biol. Chem. 276:45826-45832(2001).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
PubMed=11739175; DOI=10.1182/blood.V98.13.3699;
Aurrand-Lions M.A., Johnson-Leger C., Wong C., Du Pasquier L.,
Imhof B.A.;
"Heterogeneity of endothelial junctions is reflected by differential
expression and specific subcellular localization of the three JAM
family members.";
Blood 98:3699-3707(2001).
[3]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
AND INTERACTION WITH ITGAM.
PubMed=12208882; DOI=10.1084/jem.20020267;
Santoso S., Sachs U.J.H., Kroll H., Linder M., Ruf A., Preissner K.T.,
Chavakis T.;
"The junctional adhesion molecule 3 (JAM-3) on human platelets is a
counterreceptor for the leukocyte integrin Mac-1.";
J. Exp. Med. 196:679-691(2002).
[4]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
PubMed=11944976; DOI=10.1006/geno.2002.6742;
Phillips H.M., Renforth G.L., Spalluto C., Hearn T., Curtis A.R.J.,
Craven L., Havarani B., Clement-Jones M., English C., Stumper O.,
Salmon T., Hutchinson S., Jackson M.S., Wilson D.I.;
"Narrowing the critical region within 11q24-qter for hypoplastic left
heart and identification of a candidate gene, JAM3, expressed during
cardiogenesis.";
Genomics 79:475-478(2002).
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
TISSUE=Thalamus;
PubMed=14702039; DOI=10.1038/ng1285;
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
"Complete sequencing and characterization of 21,243 full-length human
cDNAs.";
Nat. Genet. 36:40-45(2004).
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
PubMed=12975309; DOI=10.1101/gr.1293003;
Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
Wood W.I., Godowski P.J., Gray A.M.;
"The secreted protein discovery initiative (SPDI), a large-scale
effort to identify novel human secreted and transmembrane proteins: a
bioinformatics assessment.";
Genome Res. 13:2265-2270(2003).
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=16554811; DOI=10.1038/nature04632;
Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
Sakaki Y.;
"Human chromosome 11 DNA sequence and analysis including novel gene
identification.";
Nature 440:497-500(2006).
[8]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
Venter J.C.;
Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
[9]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
TISSUE=Eye, and Uterus;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[10]
PROTEIN SEQUENCE OF 32-46.
PubMed=15340161; DOI=10.1110/ps.04682504;
Zhang Z., Henzel W.J.;
"Signal peptide prediction based on analysis of experimentally
verified cleavage sites.";
Protein Sci. 13:2819-2824(2004).
[11]
REVIEW, AND NOMENCLATURE.
PubMed=12810109; DOI=10.1016/S1471-4906(03)00117-0;
Muller W.A.;
"Leukocyte-endothelial-cell interactions in leukocyte transmigration
and the inflammatory response.";
Trends Immunol. 24:327-334(2003).
[12]
FUNCTION IN NEUTROPHIL TRANSEPITHELIAL MIGRATION, INTERACTION WITH
ITGAM, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
PubMed=15194813; DOI=10.1091/mbc.E04-04-0317;
Zen K., Babbin B.A., Liu Y., Whelan J.B., Nusrat A., Parkos C.A.;
"JAM-C is a component of desmosomes and a ligand for CD11b/CD18-
mediated neutrophil transepithelial migration.";
Mol. Biol. Cell 15:3926-3937(2004).
[13]
TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
PubMed=15994945; DOI=10.1158/0008-5472.CAN-04-4012;
Lamagna C., Hodivala-Dilke K.M., Imhof B.A., Aurrand-Lions M.;
"Antibody against junctional adhesion molecule-C inhibits angiogenesis
and tumor growth.";
Cancer Res. 65:5703-5710(2005).
[14]
GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-192 AND ASN-198.
TISSUE=Leukemic T-cell;
PubMed=19349973; DOI=10.1038/nbt.1532;
Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
Schiess R., Aebersold R., Watts J.D.;
"Mass-spectrometric identification and relative quantification of N-
linked cell surface glycoproteins.";
Nat. Biotechnol. 27:378-386(2009).
[15]
INVOLVEMENT IN HDBSCC.
PubMed=21109224; DOI=10.1016/j.ajhg.2010.10.026;
Mochida G.H., Ganesh V.S., Felie J.M., Gleason D., Hill R.S.,
Clapham K.R., Rakiec D., Tan W.H., Akawi N., Al-Saffar M.,
Partlow J.N., Tinschert S., Barkovich A.J., Ali B., Al-Gazali L.,
Walsh C.A.;
"A homozygous mutation in the tight-junction protein JAM3 causes
hemorrhagic destruction of the brain, subependymal calcification, and
congenital cataracts.";
Am. J. Hum. Genet. 87:882-889(2010).
[16]
FUNCTION IN ANGIOGENESIS, TISSUE SPECIFICITY, SUBCELLULAR LOCATION,
AND PROTEOLYTIC CLEAVAGE BY ADAM10 AND ADAM17.
PubMed=20592283; DOI=10.4049/jimmunol.1000556;
Rabquer B.J., Amin M.A., Teegala N., Shaheen M.K., Tsou P.S.,
Ruth J.H., Lesch C.A., Imhof B.A., Koch A.E.;
"Junctional adhesion molecule-C is a soluble mediator of
angiogenesis.";
J. Immunol. 185:1777-1785(2010).
[17]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=21269460; DOI=10.1186/1752-0509-5-17;
Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
"Initial characterization of the human central proteome.";
BMC Syst. Biol. 5:17-17(2011).
[18]
VARIANTS HDBSCC LYS-116 AND TYR-219, AND CHARACTERIZATION OF VARIANT
HDBSCC TYR-219.
PubMed=23255084; DOI=10.1002/humu.22263;
Akawi N.A., Canpolat F.E., White S.M., Quilis-Esquerra J.,
Morales Sanchez M., Gamundi M.J., Mochida G.H., Walsh C.A., Ali B.R.,
Al-Gazali L.;
"Delineation of the clinical, molecular and cellular aspects of novel
JAM3 mutations underlying the autosomal recessive hemorrhagic
destruction of the brain, subependymal calcification, and congenital
cataracts.";
Hum. Mutat. 34:498-505(2013).
-!- FUNCTION: Participates in cell-cell adhesion. It is a counter-
receptor for ITGAM, mediating leukocyte-platelet interactions and
is involved in the regulation of transepithelial migration of
polymorphonuclear neutrophils (PMN). The soluble form is a
mediator of angiogenesis. {ECO:0000269|PubMed:12208882,
ECO:0000269|PubMed:15194813, ECO:0000269|PubMed:20592283}.
-!- SUBUNIT: Interacts with JAM2. Interacts with ITGAM.
{ECO:0000269|PubMed:11590146, ECO:0000269|PubMed:12208882,
ECO:0000269|PubMed:15194813}.
-!- INTERACTION:
P57087:JAM2; NbExp=2; IntAct=EBI-4314733, EBI-3918416;
P50222:MEOX2; NbExp=4; IntAct=EBI-4314733, EBI-748397;
-!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass
type I membrane protein {ECO:0000305}. Cell junction, desmosome
{ECO:0000269|PubMed:15194813}. Secreted, extracellular space
{ECO:0000269|PubMed:20592283}. Note=In epithelial cells, it is
expressed at desmosomes but not at tight junctions
(PubMed:15194813). Localizes at the cell surface of endothelial
cells; treatment of endothelial cells with vascular endothelial
growth factor stimulates recruitment of JAM3 to cell-cell contacts
(PubMed:15994945).
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=2;
Name=1;
IsoId=Q9BX67-1; Sequence=Displayed;
Name=2;
IsoId=Q9BX67-2; Sequence=VSP_042561;
Note=No experimental confirmation available.;
-!- TISSUE SPECIFICITY: Highest expression in placenta, brain and
kidney. Significant expression is detected on platelets. Expressed
in intestinal mucosa cells. Expressed in the vascular endothelium.
Found in serum (at protein level). Also detected in the synovial
fluid of patients with rheumatoid arthritis, psoriatic arthritis
or ostearthritis (at protein level). {ECO:0000269|PubMed:11590146,
ECO:0000269|PubMed:11944976, ECO:0000269|PubMed:12208882,
ECO:0000269|PubMed:15194813, ECO:0000269|PubMed:15994945,
ECO:0000269|PubMed:20592283}.
-!- PTM: Proteolytically cleaved from endothelial cells surface into a
soluble form by ADAM10 and ADAM17; the release of soluble JAM3 is
increased by proinflammatory factors.
{ECO:0000269|PubMed:20592283}.
-!- DISEASE: Hemorrhagic destruction of the brain with subependymal
calcification and cataracts (HDBSCC) [MIM:613730]: A syndrome
characterized by congenital cataracts and severe brain
abnormalities apparently resulting from hemorrhagic destruction of
the brain parenchyma, including the cerebral white matter and
basal ganglia. Patients manifest profound developmental delay, and
other neurologic features included seizures, spasticity, and
hyperreflexia. The clinical course is very severe resulting in
death in infancy. Brain imaging shows multifocal intraparenchymal
hemorrhage with associated liquefaction and massive cystic
degeneration, and calcification in the subependymal region and in
brain tissue. {ECO:0000269|PubMed:21109224,
ECO:0000269|PubMed:23255084}. Note=The disease is caused by
mutations affecting the gene represented in this entry.
-!- SIMILARITY: Belongs to the immunoglobulin superfamily.
{ECO:0000305}.
-!- SEQUENCE CAUTION:
Sequence=CAC94776.1; Type=Erroneous initiation; Evidence={ECO:0000305};
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; AF356518; AAK27221.1; -; mRNA.
EMBL; AJ344431; CAC69845.1; -; mRNA.
EMBL; AF448478; AAM20925.1; -; mRNA.
EMBL; AJ416101; CAC94776.1; ALT_INIT; mRNA.
EMBL; AK074769; BAC11195.1; -; mRNA.
EMBL; AK075309; BAC11538.1; -; mRNA.
EMBL; AK125071; BAG54131.1; -; mRNA.
EMBL; AY358335; AAQ88701.1; -; mRNA.
EMBL; AP000911; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; AP001775; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; CH471065; EAW67820.1; -; Genomic_DNA.
EMBL; BC010690; AAH10690.1; -; mRNA.
EMBL; BC012147; AAH12147.1; -; mRNA.
CCDS; CCDS55799.1; -. [Q9BX67-2]
CCDS; CCDS8494.2; -. [Q9BX67-1]
RefSeq; NP_001192258.1; NM_001205329.1. [Q9BX67-2]
RefSeq; NP_116190.3; NM_032801.4. [Q9BX67-1]
UniGene; Hs.150718; -.
ProteinModelPortal; Q9BX67; -.
SMR; Q9BX67; -.
BioGrid; 123734; 7.
IntAct; Q9BX67; 3.
MINT; MINT-4085421; -.
iPTMnet; Q9BX67; -.
PhosphoSitePlus; Q9BX67; -.
SwissPalm; Q9BX67; -.
UniCarbKB; Q9BX67; -.
BioMuta; JAM3; -.
DMDM; 51701611; -.
EPD; Q9BX67; -.
PeptideAtlas; Q9BX67; -.
PRIDE; Q9BX67; -.
Ensembl; ENST00000299106; ENSP00000299106; ENSG00000166086. [Q9BX67-1]
Ensembl; ENST00000441717; ENSP00000395742; ENSG00000166086. [Q9BX67-2]
GeneID; 83700; -.
KEGG; hsa:83700; -.
UCSC; uc001qhb.4; human. [Q9BX67-1]
CTD; 83700; -.
DisGeNET; 83700; -.
EuPathDB; HostDB:ENSG00000166086.12; -.
GeneCards; JAM3; -.
HGNC; HGNC:15532; JAM3.
HPA; HPA003417; -.
HPA; HPA050434; -.
MalaCards; JAM3; -.
MIM; 606871; gene.
MIM; 613730; phenotype.
neXtProt; NX_Q9BX67; -.
OpenTargets; ENSG00000166086; -.
Orphanet; 306547; Porencephaly-microcephaly-bilateral congenital cataract syndrome.
PharmGKB; PA29993; -.
GeneTree; ENSGT00730000110678; -.
HOGENOM; HOG000247041; -.
HOVERGEN; HBG000518; -.
InParanoid; Q9BX67; -.
KO; K06785; -.
OMA; GICCAYR; -.
OrthoDB; EOG091G0DWZ; -.
PhylomeDB; Q9BX67; -.
TreeFam; TF331459; -.
Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
Reactome; R-HSA-216083; Integrin cell surface interactions.
ChiTaRS; JAM3; human.
GeneWiki; JAM3; -.
GenomeRNAi; 83700; -.
PRO; PR:Q9BX67; -.
Proteomes; UP000005640; Chromosome 11.
Bgee; ENSG00000166086; -.
CleanEx; HS_JAM3; -.
ExpressionAtlas; Q9BX67; baseline and differential.
Genevisible; Q9BX67; HS.
GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl.
GO; GO:0044291; C:cell-cell contact zone; IDA:UniProtKB.
GO; GO:0030057; C:desmosome; IDA:UniProtKB.
GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
GO; GO:0033010; C:paranodal junction; IEA:Ensembl.
GO; GO:0005886; C:plasma membrane; TAS:Reactome.
GO; GO:0043220; C:Schmidt-Lanterman incisure; IEA:Ensembl.
GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
GO; GO:0002250; P:adaptive immune response; IEA:Ensembl.
GO; GO:0001525; P:angiogenesis; IDA:UniProtKB.
GO; GO:0031103; P:axon regeneration; IEA:Ensembl.
GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
GO; GO:0030010; P:establishment of cell polarity; IEA:Ensembl.
GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
GO; GO:0002523; P:leukocyte migration involved in inflammatory response; IEA:Ensembl.
GO; GO:0042552; P:myelination; IEA:Ensembl.
GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl.
GO; GO:0001780; P:neutrophil homeostasis; IEA:Ensembl.
GO; GO:0090138; P:regulation of actin cytoskeleton organization by cell-cell adhesion; IEA:Ensembl.
GO; GO:0090022; P:regulation of neutrophil chemotaxis; IDA:UniProtKB.
GO; GO:0007286; P:spermatid development; IEA:Ensembl.
GO; GO:0019226; P:transmission of nerve impulse; IEA:Ensembl.
Gene3D; 2.60.40.10; -; 2.
InterPro; IPR007110; Ig-like_dom.
InterPro; IPR036179; Ig-like_dom_sf.
InterPro; IPR013783; Ig-like_fold.
InterPro; IPR003599; Ig_sub.
InterPro; IPR003598; Ig_sub2.
InterPro; IPR013106; Ig_V-set.
Pfam; PF07686; V-set; 1.
SMART; SM00409; IG; 2.
SMART; SM00408; IGc2; 2.
SMART; SM00406; IGv; 1.
SUPFAM; SSF48726; SSF48726; 2.
PROSITE; PS50835; IG_LIKE; 2.
1: Evidence at protein level;
Alternative splicing; Angiogenesis; Cell adhesion; Cell junction;
Cell membrane; Complete proteome; Direct protein sequencing;
Disease mutation; Disulfide bond; Glycoprotein; Immunoglobulin domain;
Membrane; Reference proteome; Secreted; Signal; Transmembrane;
Transmembrane helix.
SIGNAL 1 31 {ECO:0000269|PubMed:15340161}.
CHAIN 32 310 Junctional adhesion molecule C.
/FTId=PRO_0000015071.
TOPO_DOM 32 241 Extracellular. {ECO:0000255}.
TRANSMEM 242 262 Helical. {ECO:0000255}.
TOPO_DOM 263 310 Cytoplasmic. {ECO:0000255}.
DOMAIN 35 127 Ig-like V-type.
DOMAIN 139 236 Ig-like C2-type.
CARBOHYD 104 104 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
CARBOHYD 192 192 N-linked (GlcNAc...) asparagine.
{ECO:0000269|PubMed:19349973}.
CARBOHYD 198 198 N-linked (GlcNAc...) asparagine;
atypical. {ECO:0000269|PubMed:19349973}.
DISULFID 53 115 {ECO:0000255|PROSITE-ProRule:PRU00114}.
DISULFID 160 219 {ECO:0000255|PROSITE-ProRule:PRU00114}.
VAR_SEQ 85 135 Missing (in isoform 2).
{ECO:0000303|PubMed:14702039}.
/FTId=VSP_042561.
VARIANT 116 116 E -> K (in HDBSCC; dbSNP:rs397515439).
{ECO:0000269|PubMed:23255084}.
/FTId=VAR_069529.
VARIANT 219 219 C -> Y (in HDBSCC; the mutant is retained
in the endoplasmic reticulum;
dbSNP:rs397515438).
{ECO:0000269|PubMed:23255084}.
/FTId=VAR_069530.
CONFLICT 136 136 Q -> R (in Ref. 9; AAH10690).
{ECO:0000305}.
SEQUENCE 310 AA; 35020 MW; CE39ADF33EA1DAB9 CRC64;
MALRRPPRLR LCARLPDFFL LLLFRGCLIG AVNLKSSNRT PVVQEFESVE LSCIITDSQT
SDPRIEWKKI QDEQTTYVFF DNKIQGDLAG RAEILGKTSL KIWNVTRRDS ALYRCEVVAR
NDRKEIDEIV IELTVQVKPV TPVCRVPKAV PVGKMATLHC QESEGHPRPH YSWYRNDVPL
PTDSRANPRF RNSSFHLNSE TGTLVFTAVH KDDSGQYYCI ASNDAGSARC EEQEMEVYDL
NIGGIIGGVL VVLAVLALIT LGICCAYRRG YFINNKQDGE SYKNPGKPDG VNYIRTDEEG
DFRHKSSFVI


Related products :

Catalog number Product name Quantity
20-321-175059 JUNCTIONAL ADHESION MOLECULE-C (JAM-C) - MONOCLONAL ANTIBODY TO MOUSE JUNCTIONAL ADHESION MOLECULE-C (JAM-C); JAM-C; Junctional adhesion molecule 3; JAM-3; JAM-2 Monoclonal 0.1 mg
20-321-175060 JUNCTIONAL ADHESION MOLECULE-C (JAM-C) - MONOCLONAL ANTIBODY TO MOUSE JUNCTIONAL ADHESION MOLECULE-C (JAM-C); JAM-C; Junctional adhesion molecule 3; JAM-3; JAM-2 Monoclonal 0.1 mg
20-321-175052 JUNCTIONAL ADHESION MOLECULE-A (JAM-A) - MONOCLONAL ANTIBODY TO MOUSE JUNCTIONAL ADHESION MOLECULE-A (JAM-A) Monoclonal 0.1 mg
20-321-175173 JUNCTIONAL ADHESION MOLECULE-A (JAM-A) - MONOCLONAL ANTIBODY TO HUMAN JUNCTIONAL ADHESION MOLECULE-A (JAM-A) Monoclonal 0.1 mg
20-321-175174 JUNCTIONAL ADHESION MOLECULE-A (JAM-A) - MONOCLONAL ANTIBODY TO HUMAN JUNCTIONAL ADHESION MOLECULE-A (JAM-A) Monoclonal 0.1 mg
20-272-191449 Junctional Adhesion Molecule 1 - Mouse monoclonal [M.Ab.F11] to Junctional Adhesion Molecule 1 Monoclonal 0.05 mg
20-272-191355 Junctional Adhesion Molecule C - Rat monoclonal [CRAM-18 F26] to Junctional Adhesion Molecule C Monoclonal 0.05 mg
CC52 Junctional Adhesion Molecule B JAM-B (C-Fc-His tag) lmg
C468 Junctional Adhesion Molecule A JAM-A lmg
C468 Junctional Adhesion Molecule A JAM-A 500
C359 Junctional Adhesion Molecule B JAM-B (C-His tag) lmg
C359 Junctional Adhesion Molecule B JAM-B (C-His tag) 500
CC52 Junctional Adhesion Molecule B JAM-B (C-Fc-His tag) 500
YF-PA20322 anti-Junctional Adhesion Molecule 2 50 ul
YF-PA18761 anti-Junctional Adhesion Molecule 1 50 ug
C360 Human Junctional Adhesion Molecule B JAM-B (C-Fc-His tag) 50
C359 Human Junctional Adhesion Molecule A JAM-A l0
ARP50121_P050 JAM3(junctional adhesion molecule 3) 50 µg
CC52 Human Junctional Adhesion Molecule B JAM-B (C-His tag) l0
C481 Human Junctional Adhesion Molecule B JAM-B (C-Fc-His tag) l0
CC52 Human Junctional Adhesion Molecule A JAM-A 50
C481 Human Junctional Adhesion Molecule B JAM-B (C-His tag) 50
RPR-336 Recombinant Human Junctional Adhesion Molecule 2 5
RPR-223 Recombinant Human Junctional Adhesion Molecule 3 2
YF-MA11483 anti-Junctional Adhesion Molecule 1 (2E3-1C8) 100 ug


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur